Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
Status:
Terminated
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
Osteoporosis, a condition in which bones are fragile and break easily, is a major health
problem for postmenopausal women. Research studies have shown that both estrogen/progestin
replacement therapy (hormone replacement therapy, or HRT) and alendronate are effective in
preventing and treating osteoporosis. However, because these drugs work in somewhat different
ways, a combination of the two drugs might protect women from osteoporosis better than either
drug alone. In this study we will test whether HRT and alendronate given together for 3.5
years to postmenopausal women with low bone mass will have a greater effect on bone than
either HRT or alendronate given alone. We will also give every participant in this study
calcium and vitamin D supplements.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)